Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 17% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 30% of the time (96 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-11-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiaor equalequal tocellchronic
  Phrases that lowered it: vaccinekgmildcontainevaluate
• Sponsor's past termination rate: 3.1% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 281 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 227 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 1 (lowers risk) · Who can join
• Maximum age: 74 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 16.2% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 18 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor type: government (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 80.7% (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 47748 (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia NCT01801046 · started 2013 · scored riskier than 61% of active trials terminated
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant NCT01231412 · started 2010 · scored riskier than 49% of active trials completed
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716 · started 2010 · scored riskier than 58% of active trials terminated
• A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias NCT01287104 · started 2011 · scored riskier than 38% of active trials completed
• Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation NCT00620633 · started 2008 · scored riskier than 23% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.